Trial Profile
Phase I/II study with cisplatin and pemetrexed +/- sorafenib in malignant pleural mesothelioma (SoMe study).
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Apr 2012
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary) ; Sorafenib (Primary)
- Indications Malignant pleural effusion; Malignant-mesothelioma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SoMe
- 26 Jul 2011 New trial record